Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.

Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.

Pancreatic adenocarcinoma is the fourth lethal cancer in the United States. Many therapeutic strategies such as the chemotherapy and gene therapy have been applied as therapeutic reagents. However, there are still many limitations for ideal therapeutic outcome, which reflect drug resistance, ineffic...

Full description

Bibliographic Details
Published:
Online Access:http://hdl.handle.net/2047/d20003307
id ndltd-NEU--neu-1753
record_format oai_dc
spelling ndltd-NEU--neu-17532021-05-25T05:10:11ZMultimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.Pancreatic adenocarcinoma is the fourth lethal cancer in the United States. Many therapeutic strategies such as the chemotherapy and gene therapy have been applied as therapeutic reagents. However, there are still many limitations for ideal therapeutic outcome, which reflect drug resistance, inefficient delivery and short residence in tumor. Urgent need exists for development of novel therapeutic strategies, which could improve the dismal survival statics for pancreatic cancer patients.http://hdl.handle.net/2047/d20003307
collection NDLTD
sources NDLTD
description Pancreatic adenocarcinoma is the fourth lethal cancer in the United States. Many therapeutic strategies such as the chemotherapy and gene therapy have been applied as therapeutic reagents. However, there are still many limitations for ideal therapeutic outcome, which reflect drug resistance, inefficient delivery and short residence in tumor. Urgent need exists for development of novel therapeutic strategies, which could improve the dismal survival statics for pancreatic cancer patients.
title Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
spellingShingle Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
title_short Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
title_full Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
title_fullStr Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
title_full_unstemmed Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
title_sort multimodal therapeutic strategy for pancreatic cancer: egfr-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
publishDate
url http://hdl.handle.net/2047/d20003307
_version_ 1719406068152401920

Similar Items